Bordetella strain expressing the FHA hybrid, liposomes and vaccines
US6660261B1 · kind B1 · utility
5Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 1999 |
| Grant date | Dec 9, 2003 |
| Priority date | — |
| Expiry date | Sep 16, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin has been eliminated, or at least partially deleted or mutated so as to produce an inactive toxin. This strain can be used as vaccine. The invention also concerns liposomes containing at least part of the FHA protein and at least one protein heterologous to the FHA protein, and the use of FHA for the stimulation of immune responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.